What Structural Modifications Can Be Used for BRD4 Inhibitors for Their Use in Leukemia Therapy?

Dahong Yao,Jie Liu,Liang Ouyang

DOI: https://doi.org/10.4155/fmc-2017-0084

2017-01-01

Future Medicinal Chemistry

Abstract:A brief introduction of BRD4 inhibitors in leukemia BRD4 functions as a key chromatin reader protein, which can recognize and bind acetylated histones. BRD4 is closely involved in epigenetic processes including cell divisions and transcription regulation, which consists of 1362 amino acid residues and contains an acetyl-lysine recognition motif, two bromodomains, an NET domain and a C-terminal region [1]. According to the TCGA datasets, BRD4 shows high expression and mutation in hematological cancers. Recent studies have demonstrated that BRD4 is identified and utilized as a promising therapeutic target for several hematological cancers, especially acute myeloid leukemia (AML). Zuber et al. utilized RNAi screen to identify BRD4 as an attractive therapeutic target in AML [2]. The bromodomain small-molecule inhibitors could disrupt BRD4 recruitment to chromatin, which results in downregulation of many oncogenes, including c-MYC, BCL2 and CDK6. These events could induce reactivation of p21, a tumor suppressor, leading to cell-cycle arrest and apoptosis in hematological malignant cell lines [3,4]. In this review, we focus on summarizing several small-molecule inhibitors of BRD4 and their relevant mechanisms, as well as presenting some potential strategies for developing BRD4 inhibitors, which would provide a clue for exploiting new small molecular inhibitors targeting BRD4 in the future leukemia therapy.